Welcome to our dedicated page for QHSLab SEC filings (Ticker: USAQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QHSLab, Inc. (OTCQB: USAQ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports. QHSLab is a Nevada corporation with common stock registered under Section 12(g) of the Securities Exchange Act of 1934, and it uses these filings to report on its digital health and medical device business focused on primary care screening, assessments, and point-of-care diagnostics.
For investors analyzing USAQ, the company’s periodic reports detail revenue contributions from Integrated Service Program services, allergy diagnostic kits, immunotherapy, clinical study revenue, subscriptions, and related categories. These filings also discuss gross margin trends, operating performance, and risk factors relevant to a healthcare technology and medical devices issuer. Annual Form 10-K and quarterly Form 10-Q documents are key sources for understanding QHSLab’s business model, segment mix, and cash flow profile.
QHSLab’s Form 8-K current reports provide additional insight into material events. Recent 8-Ks describe a note repurchase agreement that extinguished defaulted convertible promissory notes, a promissory note modification and partial conversion, and a private placement of common stock and warrants to accredited investors. Other 8-Ks furnish press releases about product launches such as the Q-Cog™ cognitive assessment, corporate presentations, shareholder letters, and financial and operational updates.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight the most important points in each document. Users can quickly see what changed in a new 10-Q, how a financing or debt restructuring described in an 8-K affects capital structure, and where to find details on revenue composition, digital health initiatives, and risk disclosures. Form 4 insider transaction reports, when filed, can also be reviewed to track equity activity by QHSLab officers, directors, or significant shareholders.
QHSLab, Inc. furnished an update under Regulation FD by issuing a press release titled “QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states that the information in the press release is furnished, not filed, under the Exchange Act and is not automatically incorporated into other filings unless specifically referenced. QHSLab also emphasizes its use of its website and social media channels, including Twitter, LinkedIn, Facebook, and Instagram, as additional ways to share business and financial information that may be considered material.
QHSLab, Inc. entered into a promissory note modification and partial conversion agreement with Alex Mirakian MD PA, converting $126,548 of principal and accrued interest into 421,827 common shares at an effective price of $0.30 per share. This reduced the outstanding balance on the original 10% convertible note to $20,000 and extended its maturity date to December 31, 2026. The remaining balance is still convertible at the holder’s option at a price equal to the greater of a 25% discount to the 15‑day average market price or $0.50 per share, and the company may prepay it at any time without penalty. The shares were issued as restricted securities in a private transaction relying on Section 4(a)(2) and Rule 506 of Regulation D, with no underwriters or commissions involved.
QHSLab, Inc. disclosed that on December 26, 2025 it closed a private placement with two accredited investors for approximately
Each warrant is exercisable at
QHSLab also noted it issued a press release on
QHSLab, Inc. reported that it has launched a new product called Q-Cog™, described as supporting early detection of mild cognitive impairment and dementia. The company disclosed this by issuing a press release titled “QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia,” which is furnished as an exhibit to this report under a Regulation FD disclosure item.
The company states that the press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporation into other filings unless specifically referenced. QHSLab also highlights that it uses its website and social media channels, along with press releases, to share information that could be considered important for investors.
QHSLab, Inc. filed a Form 8-K to announce that it has made its December 2025 corporate presentation available to the public. The presentation, dated December 1, 2025, provides information about the company’s business and operations and is included as Exhibit 99.1.
The disclosure is made under Regulation FD, which is intended to ensure that important company information is shared broadly and not selectively. QHSLab states that the information in this report and the exhibit is being furnished, not filed, meaning it is not subject to certain liability provisions. The company also highlights that investors and others can access potentially material information through its website, press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) filed an 8-K to furnish a shareholder letter under Regulation FD. On November 24, 2025, the company reported that it sent a letter to its shareholders, which is attached as Exhibit 99.1. The information in this exhibit is furnished under Item 7.01, meaning it is not considered “filed” for liability purposes under Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
The company reiterates that it has no obligation to update forward-looking statements. It also highlights that investors, media, and others may receive material information through its website (usaqcorp.com), press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) entered into a Note Repurchase Agreement on November 18, 2025 to buy back its outstanding defaulted convertible promissory notes. These notes, issued in 2021 and 2022, had an aggregate outstanding balance of principal and accrued interest in excess of
QHSLab, Inc. reported Q3 2025 results. Revenue was $737,066, up from $544,285 a year ago, with gross profit of $493,631 and a steady gross margin of 67.0%. Quarterly net income was $33,411, while for the nine months year‑to‑date the company recorded a net loss of $99,156 on revenue of $1,987,931 and gross margin of 66.5%.
Operating expenses rose to support growth, led by higher sales and marketing and increased R&D tied to the QHSLab platform. Cash was $158,391 as of September 30, 2025, against total current liabilities of $2,345,536. Accounts receivable, net, were $210,131.
The company disclosed substantial doubt about its ability to continue as a going concern. It is in default on an acquisition promissory note with $461,127 of principal and accrued interest outstanding, and received default notices on two OID convertible notes with remaining principal balances of $646,841 and $462,306; default interest is accruing at 18%. On November 13, 2025, shares outstanding were 11,281,527. Management notes continued efforts to grow Integrated Service Program revenues and to discuss note terms with the current holder.
FAQ
What is the current stock price of QHSLab (USAQ)?
What is the market cap of QHSLab (USAQ)?
